Logo

The US FDA Lifts its Clinical Hold on Innate Pharma’s Clinical Evaluation of Lacutamab to Treat Sézary Syndrome

Share this
Innate

The US FDA Lifts its Clinical Hold on Innate Pharma’s Clinical Evaluation of Lacutamab to Treat Sézary Syndrome

Shots:

  • The company has reported that the US FDA has lifted the partial clinical hold placed on the IND for lacutamab earlier in Oct 2023
  • The US FDA placed a partial clinical hold on the (TELLOMAK) trial due to the death of a patients affected by Sézary Syndrome, the death was initially considered due to hemophagocytic lymphohistiocytosis (HLH). The hold was later lifted based on Innate’s review along with a committee of experts, which depicted the death to be related to an aggressive disease progression & lacutamab unrelated
  • Lacutamab is an anti-KIR3DL2 humanized cytotoxivity-inducing antibody currently being evaluated in trials for the treatment of cutaneous T-cell lymphoma (CTCL) & peripheral T cell lymphoma (PTCL)

Ref: Innate Pharma | Image: Innate Pharma

Related News:-  Innate Pharma Reports Results from the P-II Study (TELLOMAK) of Lacutamab for Sézary Syndrome

PharmaShots! Your go-to media platform for customized news ranging for multiple indications. For more information connect with us at connect@pharmashots.com

Click here to­ read the full press release 

Shivani Chandra

Shivani was a content writer at PharmaShots. She has a keen interest in recent innovations in the life sciences industry. She was covering news related to Product approvals, clinical trial results, and updates. We can be contacted at connect@pharmashots.com.

Share this article on WhatsApp, LinkedIn and Twitter

Join the PharmaShots family of 12000+ subscribers

I accept the Terms and Conditions